A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

NCT05207670 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Mosunetuzumab (Cohorts A-C)
DRUG: Mosunetuzumab (Cohorts D-E)
DRUG: Tocilizumab

Sponsor

Genentech, Inc.